more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$397.49 USD

+14.72 (3.85%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $397.55 +0.06 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

Top 37% (92 out of 251)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Zacks News

United Therapeutics (UTHR) Down 6.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research Published on August 28,2020

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UTHRPositive Net Change

United Therapeutics Announces FDA Acceptance of Tyvaso sNDA

by Zacks Equity Research Published on August 18,2020

United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

pharmaceuticals

United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat

by Zacks Equity Research Published on July 30,2020

United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

pharmaceuticals

United Therapeutics (UTHR) Q2 Earnings Meet Estimates

by Zacks Equity Research Published on July 29,2020

United Therapeutics (UTHR) delivered earnings and revenue surprises of 0.00% and 6.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

UTHRPositive Net Change

United Therapeutics (UTHR) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research Published on July 22,2020

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UTHRPositive Net Change

USANA (USNA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on July 17,2020

USANA (USNA) will release second-quarter 2020 results, which are likely to reflect impacts of the COVID-19 pandemic.

pharmaceuticals

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research Published on June 26,2020

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research Published on June 11,2020

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Why Is United Therapeutics (UTHR) Up 5% Since Last Earnings Report?

by Zacks Equity Research Published on May 29,2020

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UTHRPositive Net Change

Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics

by Zacks Equity Research Published on May 28,2020

Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics

medical

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research Published on May 27,2020

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks.com featured highlights include: SpartanNash, BG Foods, Regeneron, Vipshop and United Therapeutics

by Zacks Equity Research Published on May 14,2020

Zacks.com featured highlights include: SpartanNash, BG Foods, Regeneron, Vipshop and United Therapeutics

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research Published on May 13,2020

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected

by Zacks Equity Research Published on May 08,2020

Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research Published on May 01,2020

Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.

UTHRPositive Net Change

United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

by Zacks Equity Research Published on April 30,2020

United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters. Stock down.

pharmaceuticals

United Therapeutics (UTHR) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on April 29,2020

United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.40% and 2.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?